FDG PET-CT vs Conventional Imaging for Staging High-Risk Renal and Bladder Cancers (COPPER-T Trial)

What is it about?

The COPPER-T trial is a single-center prospective randomized controlled trial designed to compare the diagnostic accuracy of FDG PET-CT with conventional imaging (CECT scan and bone scan) for staging of clinically localized high-risk renal cell carcinoma (RCC) and urinary bladder carcinoma (T2 and above). The primary objective is to compare the diagnostic accuracy of FDG PET-CT with conventional imaging for detecting distant and nodal metastases. The study aims to provide level 1 evidence clarifying the role of FDG PET-CT in high-risk RCC and TCC of the bladder and to assess its impact on patient management. The study will also evaluate the safety of using the combined FDG PET and CECT protocol.

Featured Image

Why is it important?

This research is important because it aims to clarify the role of FDG PET-CT in the evaluation of high-risk RCC and urinary bladder carcinoma, its diagnostic accuracy compared to conventional imaging, and its impact on patient management. The study will provide level 1 evidence and help determine if FDG PET-CT should replace conventional imaging or be used only in select cases. Key Takeaways: 1. The COPPER-T trial compares FDG PET-CT with conventional imaging for staging high-risk RCC and urinary bladder carcinoma. 2. FDG PET-CT has the potential to improve diagnostic accuracy and management impact in patients with high-risk RCC and bladder cancer. 3. The study aims to determine if FDG PET-CT should replace conventional imaging or be used as an incremental diagnostic tool.